2023
DOI: 10.3390/antibiotics12071089
|View full text |Cite
|
Sign up to set email alerts
|

Bacteriophage–Antibiotic Combination Therapy against Pseudomonas aeruginosa

Abstract: Phage therapy is an alternative therapy that is being used as the last resource against infections caused by multidrug-resistant bacteria after the failure of standard treatments. Pseudomonas aeruginosa can cause pneumonia, septicemia, urinary tract, and surgery site infections mainly in immunocompromised people, although it can cause infections in many different patient profiles. Cystic fibrosis patients are particularly vulnerable. In vitro and in vivo studies of phage therapy against P. aeruginosa include b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 60 publications
(66 reference statements)
0
1
0
Order By: Relevance
“…My suspicion, in fact, is that in explicit terms, this math may be less useful than can be the case for preclinical studies, if only because there is less opportunity to make the detailed measurements that many of these models require, e.g., such as of bacterial concentrations, phage titers in association with targeted bacteria, phage adsorption rate constants, phage burst sizes, etc. These are all as found in situ while treating infections caused by what are typically somewhat uncharacterized bacterial strains and, in many cases, also in combination with antibiotics [ 41 , 57 , 86 , 87 , 88 , 89 ], which can have antagonistic impacts on phage infection abilities [ 41 , 51 , 85 , 90 ]. In particular for the latter, note that of 18 clinical phage therapy studies that I was able to obtain—published in 2023 or, at the time of writing, which are published but still online ahead of print—at least 16 indicate treatments using phages in combination with antibiotics [ 57 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 ].…”
Section: Discussionmentioning
confidence: 99%
“…My suspicion, in fact, is that in explicit terms, this math may be less useful than can be the case for preclinical studies, if only because there is less opportunity to make the detailed measurements that many of these models require, e.g., such as of bacterial concentrations, phage titers in association with targeted bacteria, phage adsorption rate constants, phage burst sizes, etc. These are all as found in situ while treating infections caused by what are typically somewhat uncharacterized bacterial strains and, in many cases, also in combination with antibiotics [ 41 , 57 , 86 , 87 , 88 , 89 ], which can have antagonistic impacts on phage infection abilities [ 41 , 51 , 85 , 90 ]. In particular for the latter, note that of 18 clinical phage therapy studies that I was able to obtain—published in 2023 or, at the time of writing, which are published but still online ahead of print—at least 16 indicate treatments using phages in combination with antibiotics [ 57 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 ].…”
Section: Discussionmentioning
confidence: 99%